Figures
Abstract
Background
Cardiovascular disease is the leading cause of mortality in hemodialysis patients and is associated with chronic inflammation. Elevation of uremic toxins, particular protein-bound uremic toxins, is a possible cause of hyper-inflammation in hemodialysis patients. But the association between uremic toxins and inflammatory markers in hemodialysis is still unclear.
Methods
We conducted a cross-sectional study to evaluate the association of the serum uremic toxins and inflammatory markers in hemodialysis patients.
Results
The uremic toxins were not associated with inflammatory markers- including high sensitivity C-reactive protein, IL(Interleukin) -1β, IL-6, tumor necrosis factor-α. In multiple linear regression, serum levels of total p-cresol sulfate (PCS) were independently significantly associated with serum total indoxyl sulfate (IS) (standardized coefficient: 0.274, p<0.001), and co-morbidity of diabetes mellitus (DM) (standardized coefficient: 0.342, p<0.001) and coronary artery disease (CAD) (standardized coefficient: 0.128, p = 0.043). The serum total PCS levels in hemodialysis with co-morbidity of DM and CAD were significantly higher than those without co-morbidity of DM and CAD (34.10±23.44 vs. 16.36±13.06 mg/L, p<0.001). Serum levels of total IS was independently significantly associated with serum creatinine (standardized coefficient: 0.285, p<0.001), total PCS (standardized coefficient: 0.239, p = 0.001), and synthetic membrane dialysis (standardized coefficient: 0.139, p = 0.046).
Citation: Hsu H-J, Yen C-H, Wu I-W, Hsu K-H, Chen C-K, Sun C-Y, et al. (2014) The Association of Uremic Toxins and Inflammation in Hemodialysis Patients. PLoS ONE 9(7): e102691. https://doi.org/10.1371/journal.pone.0102691
Editor: Francesca D'Addio, San Raffaele Hospital, Italy
Received: January 7, 2014; Accepted: June 20, 2014; Published: July 22, 2014
Copyright: © 2014 Hsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the Chang Gung Memorial Hospital Research Fund (CMRPG260363). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
End stage renal disease (ESRD) patients had higher cardiovascular disease (CVD)-related and all-cause mortality. Hyper-inflammation in hemodialysis patients results in CVD [1], [2]. Pro-inflammatory cytokines are crucial to the inflammation associated with malnutrition and atherosclerosis in ESRD. Furthermore, it has been shown that high sensitivity C-reactive protein (hs-CRP) is elevated in patients with chronic kidney disease (CKD).
Uremic toxins can be classified into small water soluble uremic toxins, middle molecule uremic toxins, and protein bound uremic toxins. Due to substantial albumin binding, current dialysis modality could provide adequate removal of small water soluble uremic toxins and partial removal of middle molecule uremic toxins, but difficult in protein-bound uremic toxins [3]. P-cresol sulfate (PCS) and indoxyl sulfate (IS) are protein-bound uremic toxins and were associated with endothelial dysfunction also immune dysregulation in renal disease [4], [5]. The cytokines' clearance decreases as well as the chronic renal failure stage increases. Many inflammatory cytokines are classified between the uremic toxins in particular tumor necrosis factor (TNF)- α, Interleukin(IL)-6, IL-1β are considered middle molecules as well as β2 microglobulin [6]. However, the exact association between uremic toxins and inflammation in ESRD patients is still not fully understood. Hence, we conducted the cross-sectional study to evaluate the association between uremic toxins and inflammatory markers.
Subjects and Methods
Patients
We conducted a cross-sectional study at the dialysis center of the Chang Gung Memorial Hospital, Keelung, Taiwan, enrolling 295 chronic hemodialysis patients who had been undergoing regular hemodialysis for more than 6 months. Excluded from the study were those patients who were under 20 years of age, admitted for acute illnesses, using hemodiafiltration, affected by immunologic disease, assuming steroid therapy, and had declined participation (Figure 1). All patients had been receiving a standardized hemodialysis regimen: dialysate flow, 500 mL/min; blood flow, 250–300 mL/min, duration of dialysis per session, 4 h; and, thrice-weekly hemodialysis. We screened the serum uremic toxins (blood urea nitrogen (BUN), creatinine, β2 microglobulin, total PCS and IS, and inflammatory markers (hs-CRP, IL-1β, IL- 6, TNF- α) in the study patients. The uremic toxins and cytokines were checked during the normal hemodialysis week. The information about dialysis membrane type, vascular access type, anticoagulation type, and angiotensin converting enzyme inhibitor (ACEI)/angiotensin II type 1 receptor blocker (ARB) assuming was recorded. All written informed consent for participation in the study was obtained from participants. This study complies with the Declaration of Helsinki and was approved by the Ethics Committee of the Institutional Review Board at Chang Gung Memorial Hospital.
Measurement of the serum concentrations of total IS and PCS
To determine total IS and PCS serum levels, serum samples were deproteinized by adding 3 parts methanol to 1 part serum. All analyses were performed using a Waters Acquity Ultra Performance Liquid Chromatography (UPLC) system (Milford, MA, USA).
Statistical Analysis
Continuous variables were expressed as means ± standard deviations. For normally distributed continuous variables, a two-tailed Student's unpaired t-test was employed to evaluate the differences between the means. The differences between groups of categorical variables were analyzed by the χ2 test or Fisher's exact test. To examine the relationship between IS/PCS and other variables, Pearson's correlation test was used. To identify independent associations, stepwise multiple regression analysis was used, and co-variants selection based on univariate analysis with variables with p<0.1 were selected. We considered p<0.05 statistically significant. All analyses were performed using SPSS version 17.0 for Windows.
Results
Study subjects
The mean age of the patients (99 men and 110 women) was 58.2±13.8 years old; while the mean duration of dialysis was 67.2±54.8 months (table 1). There were 75 (36% of the total study patients) diabetic patients in our study and all were type 2 diabetes mellitus (DM). All patients used anti-coagulation agents with 76.6% patients (n = 160) using heparin whereas 23.4% patients (n = 49) using low-molecular-weight heparin. There were 72.7% patients (n = 152) used arterial venous fistula as hemodialysis access. The prevalence of ACEI/ARB use in study patients was 34.4%. The biochemical and dialysis related parameters were shown in table 2. The serum levels of total IS and total PCS in the study patients were 36.70±16.74 and 21.25±17.81 mg/L, respectively.
Relationship between hemodialysis type, uremic toxins, and inflammatory markers
The associations among hemodialysis type, uremic toxins, and inflammatory markers are shown in table 3. Vascular access type was not significantly associated with uremic toxins and inflammatory markers. Hemodialysis synthetic membrane use was significantly associated with serum total IS (correlation coefficient: 0.195, p<0.001). High flux dialysis was also significantly associated with serum total IS (correlation coefficient: 0.159, p = 0.024). However, hemodialysis synthetic membrane or high flux dialysis was not associated with inflammatory markers- hs-CRP, IL-1β, IL-6, and TNF-α. In protein-bound uremic toxins, serum IS was positively associated with serum total PCS (correlation coefficient: 0.292, p<0.001). However, these was no association between serum IS and inflammatory markers- hs-CRP, IL-1β, IL-6, and TNF-α. Serum PCS was positive associated with serum total IS and not associated with inflammatory markers- hs-CRP, IL-1β, IL-6, and TNF-α. In the inflammatory markers, serum hs-CRP was positively associated with serum IL-6 and TNF-α. Serum IL-6 was positively associated with serum hs-CRP and TNF-α. However, IL-1β was not associated with other inflammatory markers - hs-CRP, IL-6, and TNF-α.
Factors associated with serum levels of total PCS
In order to cognize the factor associated with serum levels of total PCS, univariate correlation analysis was performed first. The univariate analysis revealed that the total PCS levels were positively associated with the presence of DM (correlation coefficient: 0.322, p<0.001), coronary artery disease (CAD) (correlation coefficient: 0.213, p = 0.003), stroke (correlation coefficient: 0.172, p = 0.017), and serum levels of BUN (correlation coefficient: 0.173, p = 0.014) and hemoglobin (correlation coefficient: 0.169, p = 0.017) (table 4). Besides, there was a positive association between the serum levels of total PCS and IS (correlation coefficient: 0.292, p<0.001). There was also a trend of partial positive association between presence of peripheral arterial occlusive disease (PAOD) and serum total PCS. However, inflammatory cytokine levels were not significantly associated with the serum total PCS levels. Stepwise multiple regression analysis revealed that the presence of DM and CAD, and the serum levels of total IS were independent factors associated with the serum total PCS levels after adjustment of age, gender, and factors that significant in univariate analysis (comorbidity of PAOD and stroke, serum levels of BUN and hemoglobin). Besides, there was a trend of positive association between presence of stroke and serum total PCS after multiple regression analysis. Co-morbidity of PAOD lost the trend of association with the serum total PCS levels after multiple regression analysis.
Factors associated with serum levels of total PCS according to age
To assess the association between age, uremic toxins and co-morbidity, the study patients were grouped into older patients (Age ≧59 years old) and younger patients (Age <59 years old) by median age. In older patient group, serum total PCS levels were positively associated with co-morbidity of DM, CAD, stroke and serum levels of total IS (table 5). However, presence of DM (standardized coefficient: 0.399, p<0.001), stroke (standardized coefficient: 0.190, p = 0.034) and serum total IS (standardized coefficient: 0.266, p = 0.003) were independent factors associated with serum total PCS after multiple regression analysis. In younger patient group, serum total PCS levels were positively associated with presence of PAOD, and serum BUN and total IS. After multiple regression analysis, co-morbidity of PAOD (standardized coefficient: 0.260, p = 0.008) and serum total IS levels (standardized coefficient: 0.315, p = 0.001) were independent factors associated with serum total PCS.
Factors associated with serum levels of total IS
The analysis revealed that the total IS levels were positively associated with male gender (correlation coefficient: 0.153, p = 0.029), serum levels of BUN (correlation coefficient: 0.143, p = 0.041), creatinine (correlation coefficient: 0.311, p<0.001), and total PCS levels (correlation coefficient: 0.292, p<0.001) (table 6). Moreover, the serum total IS levels were also strongly associated with synthetic membrane use (correlation coefficient: 0.195, p<0.001) and high flux dialysis (correlation coefficient: 0.159, p<0.001). There was also a trend of partial positive association between presence of CAD and serum total IS. Then stepwise multiple regression analysis revealed that synthetic membrane use (standardized coefficient: 0.139, p = 0.046) and serum levels of creatinine (standardized coefficient: 0.285, p<0.001) and total PCS (standardized coefficient: 0.239, p = 0.001) were independent factors associated with the serum total IS levels. Inflammatory markers including hs-CRP and cytokine levels were not associated with the serum total IS levels. Co-morbidity of CAD, PAOD, and stroke was also not independently associated with the serum total IS levels.
Factors associated with serum levels of total IS according to age
In older patient group (Age ≧59 years old), serum total IS levels were positively associated with serum creatinine and total PCS (table 7). Serum total PCS levels (standardized coefficient: 0.224, p = 0.021) were independent factors associated with serum total IS after multiple regression analysis. In younger patient group (Age <59 years old), serum total IS levels were positively associated with male gender, and serum levels of creatinine and total PCS, and synthetic membrane use. After multiple regression analysis, only serum total PCS (standardized coefficient: 0.274, p = 0.004) and synthetic membrane use (standardized coefficient: 0.241, p = 0.012) were independent factors associated with serum total IS.
Comparison of serum levels of total PCS in hemodialysis patients with comorbidity of DM and CAD or not
Due to co-morbidity of DM was independently associated with serum levels of total PCS. The baseline characteristics and also biochemical and dialysis-related parameters were also analysis according to the presence or absence of DM (table 8 and table 9). Those hemodialysis patients with DM were older, shorter dialysis vintage, with more cigarette smoking, higher prevalence of co-morbidity of CAD, PAOD, stroke, and lower serum level of creatinine, intact parathyroid hormone (i-PTH), Kt/V and urea reduction rate (URR). Besides, higher serum levels of total PCS were noted in those patients with diabetes than those without diabetes (DM patients vs. non DM patients: 29.36±21.59 vs. 17.38±13.77 mg/L, p<0.001). Furthermore, previous multiple linear regression analysis showed that comorbidity of CAD was also independently significantly associated with serum total PCS. The serum levels of total PCS were also compared between those patients with comorbidity of CAD or not. Those patients with comorbidity of CAD had higher serum levels of total PCS than those without CAD (CAD patients vs. non CAD patients: 29.94±21.02 vs. 19.97±16.75 mg/L, p = 0.003) (data also not shown in table). In order to configure out the association of serum total PCS and comorbidity of DM and CAD, patients were divided into four groups: those with comorbidity of DM and CAD; with comorbidity of DM but no CAD; with comorbidity of CAD but not DM; with comorbidity of neither DM nor CAD. We compared the serum total PCS levels between those four groups of patients. In hemodialysis patients with DM, the serum levels of PCS in those patients with CAD (n = 19) were higher than patients without CAD (n = 56) though without significance (34.10±23.44 vs. 27.60±20.83 mg/L, p = 0.297) (figure 2). In hemodialysis patients without DM, the serum levels of PCS in those patients with CAD (n = 19) were significantly higher than those patients without CAD (n = 115) (24.68±16.80 vs. 16.36±13.06 mg/L, p = 0.028). The serum levels of PCS in those patients with DM but not CAD (n = 56) were significantly higher than those neither DM nor CAD (n = 115) (27.60±20.83 vs. 16.36±13.06 mg/L, p<0.001). Besides, serum levels of total PCS in those patients with DM but not CAD (n = 56) were higher than those with CAD but not DM (n = 19): (27.60±20.83 vs. 24.68±16.80 mg/L, p = 0.620) though without significance. Moreover, serum levels of total PCS in those patients with DM and CAD (n = 19) were significantly higher than those with neither DM nor CAD (n = 115): (34.10±23.44 vs. 16.36±13.06 mg/L, p<0.001).
Comparison of serum levels of total IS in hemodialysis patients with comorbidity of DM and CAD or not
The serum levels of total IS were compared between those patients with comorbidity of DM or not. Those hemodialysis patients with comorbidity of DM and those without diabetes had similar levels of total IS (DM patients vs. non DM patients: 35.19±14.60 vs. 38.49±17.54 mg/L, p = 0.182). Furthermore, the serum levels of total IS were also compared between those patients with comorbidity of CAD or not. Those patients with comorbidity of CAD had higher serum levels of total IS than those without CAD although without significance (CAD patients vs. non CAD patients: 41.86±14.82 vs. 36.25±16.81 mg/L, p = 0.067) (data also not shown in table). In order to configure out the association of serum total IS and comorbidity of DM and CAD, patients were also divided into four groups: those with comorbidity of DM and CAD; with comorbidity of DM but no CAD; with comorbidity of CAD but not DM; with comorbidity of neither DM nor CAD. In hemodialysis patients with DM, the serum levels of total IS in those patients with CAD (n = 19) were higher than patients without CAD (n = 56) (38.90±10.86 vs. 33.74±15.68 mg/L, p = 0.181) (figure 3). In hemodialysis patients without DM, the serum levels of total IS in those patients with CAD (n = 19) were higher than those patients without CAD (n = 115) (45.55±18.36 vs. 37.44±17.26 mg/L, p = 0.084). The serum levels of total IS in those patients with DM but not CAD (n = 56) were lower than those with neither DM nor CAD (n = 115) (33.74±15.68 vs. 37.44±17.26 mg/L, p = 0.196). Besides, serum levels of total IS in those patients with DM but not CAD (n = 56) were significantly lower than those with CAD but not DM (n = 19): (33.74±15.68 vs. 45.55±18.36 mg/L, p = 0.014). Moreover, serum levels of total IS in those patients with DM and CAD (n = 19) were lower than those CAD but not DM (n = 19): (38.90±10.86 vs. 45.55±18.36 mg/L, p = 0.185). Furthermore, previous univariate analysis found that serum levels of IS were associated with high flux dialysis. Biochemical and dialysis-related parameters were also compared between those patients with high flux and low flux dialysis. Those patients with high flux dialysis had higher serum levels of BUN, creatinine, hemoglobin, albumin, total IS, and URR (table 10).
Discussion
The mechanism of inflammation and higher CVD in ESRD patients under hemodialysis is multifactorial. Uremic toxins were considered one of possible cause to induce inflammation and CVD. In this study, the uremic toxins including small soluble, middle molecular, and protein-bound uremic toxins were all evaluated. The result showed that there was no significant association between above uremic toxins and inflammatory markers (hs-CRP, IL-1β, IL-6, and TNF-α). Furthermore, the serum levels of PCS were significantly higher in DM and CAD patients.
Malnutrition, inflammation, atherosclerosis syndrome is associated with an exceptionally high mortality rate in ESRD patients [2]. Elevations of several inflammatory markers including CRP, IL-6, and TNF-alpha were reported to be associated with mortality in ESRD patients undergoing hemodialysis or peritoneal dialysis [7], [8], [9], [10]. Although the causes of elevated serum levels of pro-inflammatory cytokines in ESRD patients are not well understood, reduced renal clearance of cytokines, accumulation of advanced glycation end-products (AGE), hyperhomocysteinemia [11], dialysis procedure- related inflammation [12], and unrecognized persistent infection were considered to induce the inflammation in ESRD patients. Uremic toxins, especially protein-bound uremic toxins, are also considered to cause inflammation [13], [14]. Protein-bound uremic toxins cannot be easily removed during dialysis procedure not matter HD or PD. In vitro studies had shown that p- cresol had toxic potential to endothelium. Clinical studies also showed significant association between serum PCS and CVD in CKD and ESRD patients [15], [16], [17], [18], [19]. Lee et al. found significant association between serum levels of free IS and IL-6 in peritoneal dialysis patients. But no significant association between serum levels of total IS and CRP, IL-6, and IL-10 was noted [20]. However, few studies exploded the association between uremic toxins and pro-inflammatory markers in hemodialysis patients. The study evaluated the uremic toxins including serum BUN, creatinine, β2 microglobulin, total PCS, and IS with association of pro-inflammatory cytokines in hemodialysis patients. The result showed lack association of uremic toxins and pro-inflammatory markers. Possible explanation is that inflammation induced by uremic toxins is transiently or focally, which cannot be observed by our study design. It is also possible that PCS directed induced atherosclerosis without via the cytokine and inflammation. The mechanism needs more studies to evaluate the close connection between total PCS and atherosclerosis in ESRD patients.
It is very interesting that serum total PCS was significantly associated with comorbidity of DM and also CAD. The exact connection between co-morbidity of DM, CAD, and serum total PCS was unclear. Because of the study design does not allow to establish any causal relationship between variable above that were examined. However, some working hypothesis can be considered. Possible hypotheses are that those patients with co-morbidity of CAD and DM had some particular factors that influence the levels of PCS production. But lots of evidences suggested that higher levels of PCS induced CAD by causing the deleterious effect on the endothelium. So the relationship between serum levels of total PCS and comorbidity of CAD could be understood and solved. But the association between serum total PCS and co-morbidity of DM is still unknown. Similarly, Meijers et al. also showed significant higher total and free PCS in hemodialysis patients with DM than non- DM [15]. Whether this is related to particular dietary habits is not clear. Indeed, protein intake is a limiting factor for the production by gut resident bacteria of p cresol. However, we can reasonable exclude this hypothesis because we did not observe any statistically significant difference among the study patients with DM or not in the serum albumin, BMI, and nPCR. Residual renal function and high flux hemodialysis were also important factors to determine protein-bound uremic toxins [21], [22]. However, the residual renal function and high flux dialysis use ratio did not significant between DM and non-DM patients (table 8). Another possible explanation is that patients with diabetes have a significant risk of developing severe constipation often due to dysfunction of the autonomic nervous system [23]. Some evidences suggests diabetic patients had altered colonic protein fermentation [24]. P-cresol was generated by the intestinal flora and then conjugated to p-cresol sulfate in the intestinal wall and to p-cresylglucuronide in the liver [3]. When bowel movement decreased due to autonomic dysfunction in DM patients, more gut formation and production of PCS may happen.
In hemodialysis patients with DM, although the difference was not prominent significance, there was a trend that the serum levels of total p-cresol sulfate were higher in those patients with co-morbidity of CAD than those without CAD. These result indicated that higher serum total PCS may be associated with CAD even in these high CVD risk patients (diabetic hemodialysis patients). The reason of no significance may be due to small patient number (patients with DM & CAD: n = 19 vs. DM without CAD: n = 56). In hemodialysis patients without DM, the serum levels of total p-cresol sulfate were significantly higher in those patients with co-morbidity of CAD than those without CAD. The results suggested that particular dietary habit or colonic protein fermentation in those HD patients may develop coronary artery disease no matter in DM or non-DM patients. In stratified analysis by age, serum levels of total PCS were independently significantly associated with comorbidity of stroke in older patients. But serum levels of total PCS was independently significantly associated with co-morbidity of PAOD in younger patients. All these results showed that serum total levels of PCS were highly associated with atherosclerosis-related disease such as CAD, stroke, and PAOD in CKD patients with hemodialysis. But the association between the serum levels of total IS and co-morbidity of CAD, stroke, and PAOD is lacking in the study. Some studies found that serum levels of IS in hemodialysis patients is associated with markers related to atherosclerosis [4]. Because of the controversial results, the exact association between serum levels of IS and atherosclerosis-related comorbidity in CKD patients need further evaluation.
The study had several limitations. The free-form PCS and IS levels were not checked. Furthermore, the mechanism of the higher total-form PCS in the DM patients could not be determined. However, this is an important study to evaluate the pro-inflammatory cytokines and protein-bound uremic toxins in hemodialysis patients. In addition, this study found that serum total PCS levels were significantly higher in hemodialysis patients with comorbidity of CAD and DM than those without co-morbidity of DM and CAD. This gave us the clue that development of CVD in hemodialysis patients with co-morbidity of DM maybe associated higher total PCS due to particular dietary habits and also DM-related alternation in colonic protein fermentation. Besides, due to the constraints of this study design (cross-sectional design), we are not able to provide a powerful evidence for the correlation between serum levels of IS or PCS with survival. However, Wang et al. had found association between high total p-cresol sulfate and major adverse cardiac events in CKD patients [25]. Wu et al. also showed that serum free p-cresol sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients [17]. All of the results strongly proved the association between cardiovascular disease- related clinical outcome and serum levels of PCS in CKD patients.
In conclusion, the study showed that uremic toxins including total PCS and IS were not associated with pro-inflammatory markers in ESRD patients with hemodialysis. Besides, serum levels of total PCS was independently significantly associated with co-morbidity of CAD and DM.
Author Contributions
Analyzed the data: HJH CHY IWW KHH. Contributed reagents/materials/analysis tools: CKC CYS CCC. Wrote the paper: HJH MSW CCL. Participated in data interpretation: CYC CJT.
References
- 1. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, et al. (2003) Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 42: A5–230, A5-7, S1-230.
- 2. Pecoits-Filho R, Lindholm B, Stenvinkel P (2002) The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrol Dial Transplant 17 Suppl 11: 28–31.
- 3. Martinez AW, Recht NS, Hostetter TH, Meyer TW (2005) Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 16: 3430–3436.
- 4. Raff AC, Meyer TW, Hostetter TH (2008) New insights into uremic toxicity. Curr Opin Nephrol Hypertens 17: 560–565.
- 5. De Smet R, Dhondt A, Eloot S, Galli F, Waterloos MA, et al. (2007) Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 22: 2006–2012.
- 6. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, et al. (2003) Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63: 1934–1943.
- 7. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648–658.
- 8. Yeun JY, Levine RA, Mantadilok V, Kaysen GA (2000) C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469–476.
- 9. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, et al. (1998) Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236–244.
- 10. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, et al. (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107–114.
- 11. Cianciolo G, La Manna G, Coli L, Donati G, D'Addio F, et al. (2008) 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol 28: 941–948.
- 12. Stefoni S, Coli L, Cianciolo G, Donati G, Dalmastri V, et al. (2003) In vivo evaluation of cellular and inflammatory response to a new polyethersulfone membrane. Contrib Nephrol 68–79.
- 13. Glorieux G, Cohen G, Jankowski J, Vanholder R (2009) Platelet/Leukocyte activation, inflammation, and uremia. Semin Dial 22: 423–427.
- 14. Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, et al. (2013) Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 93: 837–845.
- 15. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1174–1180.
- 16. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, et al. (2010) Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25: 1183–1191.
- 17. Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, et al. (2012) Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrol Dial Transplant 27: 1169–1175.
- 18. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, et al. (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5: 1182–1189.
- 19. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, et al. (2005) Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 16: 3381–3388.
- 20. Lee CT, Kuo CC, Chen YM, Hsu CY, Lee WC, et al. (2010) Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis. Perit Dial Int 30: 456–463.
- 21. Brunet P, Dou L, Cerini C, Berland Y (2003) Protein-bound uremic retention solutes. Adv Ren Replace Ther 10: 310–320.
- 22. Marquez IO, Tambra S, Luo FY, Li Y, Plummer NS, et al. (2011) Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6: 290–296.
- 23. Welch AC (2003) Constipation & diabetes. Constipation can affect up to 60 percent of people with diabetes. Some treatments may work better than others. Which ones are right for you? Diabetes Forecast 56: 65–66.
- 24. Todesco T, Zamboni M, Armellini F, Bissoli L, Turcato E, et al. (1993) Plasma acetate levels in a group of obese diabetic, obese normoglycemic, and control subjects and their relationships with other blood parameters. Am J Gastroenterol 88: 751–755.
- 25. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, et al. (2013) Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. J Nephrol 26: 111–118.